The key messages for rheumatologists vis-à -vis leprosy are (i) remember leprosy causes granulomatous skin lesions and neuropathy; (ii) leprosy may present in patients from leprosy endemic countries years after leaving; (iii) consider leprosy when rheumatological tests are negative; (iv) look for skin lesions in people with peripheral neuropathy; (v) refer to a tropical specialist to have leprosy excluded; (vi) over 50% leprosy patients have inflammation in skin and nerve. It is important to diagnose leprosy early because then anti-bacterial treatment can be initiated and peripheral nerve damage minimized. Leprosy is often a late or missed diagnosis in the UK leprosy patients present with a range of lesions, depending on their underlying immunity to Mycobacterium leprae. Skin lesions include granulomatous lesion, papules, nodules and infiltration. The peripheral neuropathy is associated with nerve trunk damage. Leprosy may also present with acute inflammatory episodes called reactions which mimic vasculitis. We have a cohort of 145 patients in London, UK who have been diagnosed with leprosy in the last 16 years and have found significant delays in diagnosis. The geographical and ethnic profile of patients reflects migration patterns to the UK, 54% of our patients come from the Indian sub-continent, followed by Brazil and Nigeria. Misdiagnoses were made dermatologists, neurologists and rheumatologists. Granulomatous lesions were often diagnosed as sarcoid or cutaneous TB. Leprosy is essentially a clinical diagnosis, made by recognizing skin lesions and peripheral neuropathy. Skin biopsy can help support a diagnosis of leprosy and the typical findings will be shown. I shall also review leprosy patients who were initially seen in rheumatology clinics and misdiagnosed with vasculitis and GPA. Current treatments with the WHO multi-drug combinations (rifampicin, dapsone and clofazimine) are highly effective with relapse rates <1 % year. There is no clinical evidence of significant rifampicin resistance.
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All patients need to be tested for nerve damage and 60% will have evidence of nerve damage. About 50% of leprosy patients need a course of steroid treatment for their immune mediated skin and nerve damage. The outcomes with steroid treatment are disappointing. We have done trials using methylprednisolone as an early treatment for leprosy reactions but did not find any benefit. 50% of patients needed a further course of steroids. We have also done a study using AZA to treat leprosy reactions. We also found no benefit from adding in this immune-suppressant. Other treatments are needed to stop inflammation. Neuropathic pain is also a newly recognized complication of leprosy and a risk factor is having had immune mediated reactions Disclosure statement: The author has declared no conflicts of interest. Intra-articular steroid therapy is widely used in the management of painful OA, and included in current guidelines for the disease. The advantage of IA delivery is that it permits relatively high dose therapy targeted to the joint whilst minimizing systemic side effects. Steroids have marked anti-inflammatory effects and it is thought that their analgesic effect may be related to their anti-inflammatory effect. Synovitis is a feature of the OA phenotype and steroids have been shown using MRI to reduce synovial volume though the relationship between OA synovitis and pain remains uncertain. Intra-articular steroid therapy has been used in many sites of OA including the knee, hip, hands and spine. Most of the data relating to efficacy of therapy is in knee OA, though there have been a small number of randomized trials of IA steroid therapy in patients with hip and thumb OA. Data from meta-analyses and also Cochrane review of IA steroid therapy in knee OA suggests that treatment is associated with a significant reduction in pain in the short term (< 3 weeks). There was less certainty, however, about the longer term benefit and also evidence of any efficacy for functional improvement. Furthermore there was insufficient data to favour any particular steroid preparation or dose of therapy. In general IA therapy is well tolerated; adverse effects are well known and include local fat atrophy, transient increase in joint pain and flushing, and rarely joint infection. Absorption of injected steroid from the joint into the circulation is recognized though does not appear to be associated with any clinically significant systemic effects.
CONTROVERSIES IN OSTEOARTHRITIS THERAPEUTICS
Evidence from clinical trials, primarily in knee OA, suggests significant variation in both response to IA steroid therapy and, among those who respond, to the duration of response. Some of the variation may be explained by technical factors including the accuracy of injection and use of image guidance. Patient and disease related factors may also play a role. There are few studies, however, which have looked systematically at predictors of response and the limited data available do not confirm any factors consistently linked with response. Larger studies including more detailed assessment of both patient and disease related factors are therefore needed to better define those who are most likely to benefit. Disclosure statement: The author has declared no conflicts of interest. DMARDs are used in RA for their effect on the primary disease inflammatory process, resulting in reduction in symptoms and retardation of structural joint damage. Such DMARDs were historically not considered for OA since it was not primarily an inflammatory arthritis. A long history of focus on chondroprotective therapies and failed structure-modification trials may have contributed to this frame of mind. It is well known that inflammation is present in OA, with biopsy studies demonstrating histological synovitis detected at the time of the earliest chondral damage. In terms of cellular make up, there is cellular infiltration with macrophages, activated T and B cells and vascular proliferation. Though cytokine levels are often less than in RA, they are still elevated compared with normal controls, with a similar pattern to RA. The application of modern imaging modalities such as MRI and ultrasound to OA has led to important advances in understanding of the OA phenotype. In typical symptomatic OA, MRI has demonstrated abundant pathology and synovitis has been reported extremely commonly, with detection reflecting the sensitivity of the imaging tool employed. Although generally less in volume and vascularity than in RA, this imaging-detected synovitis has been associated with the pain of OA, and also independently associated with progression to knee joint replacement. How can we use the presence of inflammation in OA to improve therapy of OA? Of our current symptomatic pharmacological agents, the two with consistently modest analgesic effect sizes are NSAIDs and IA corticosteroids-both of which have significant anti-inflammatory actions. PsA has multiple, diverse clinical and radiographic presentations. This diversity interferes with the development of simple treatment algorithms and, historically, there has been little work done on early aggressive treatment and the effect of traditional DMARDs on characteristic features of the disease such as enthesitis and dactylitis. Evidence favouring MTX, the most commonly used drug in PsA, is mostly observational. The design of clinical trials has been hampered by the lack of appropriate outcome measures, now being corrected by organizations such as GRAPPA. In the last few years data are now emerging on the outcomes of early intervention and new drugs, and new targets, are becoming available. These issues will be reviewed in this presentation. Disclosure statement: P.H. has received honoraria from AbbVie, Celgene, Janssen, Novartis, Pfizer, BMS, Merck and UCB. Dermatologists and rheumatologists share the management of patients with a broad spectrum of clinical conditions that affect both the musculoskeletal system and the skin. Psoriasis and PsA is probably our most common link. We have witnessed the graduation from the gold treatment era, messy topical treatments such as tar and dithranol, diminishing availability of inpatient beds to the evolution of sophisticated patient targeted treatments. Intractable psoriasis and mutilating arthropathy are fortunately now a fairly rare occurrence. However there are new challenges such as paradoxical cutaneous side effects and a reduced immune surveillance that may allow skin cancers to thrive. How best can the two specialities interact to provide a patient centred system of care which is also efficient and economic? It is important that rheumatologists and dermatologists appreciate their similarities in approach to disease management but also our unique methods of assessment and treatment of complex disease such as psoriasis/PsA and cutaneous lupus. A variety of clinical examples of rheumatic skin disorders seen over a number of years will serve to illustrate points of diagnosis and treatment. Disclosure statement: L.B. has served on advisory boards for AbbVie, Pfizer and Janssen-Cilag.
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